Literature DB >> 28094262

Radiotherapy and immunotherapy: a beneficial liaison?

Ralph R Weichselbaum1, Hua Liang1, Liufu Deng1, Yang-Xin Fu2.   

Abstract

Investigations into the interaction between radiotherapy and the host immune system have uncovered new mechanisms that can potentially be exploited to improve the efficacy of radiotherapy. Radiation promotes the release of danger signals and chemokines that recruit inflammatory cells into the tumour microenvironment, including antigen-presenting cells that activate cytotoxic T-cell function. By contrast, radiation can attract immunosuppressive cells into the tumour microenvironment. In rare circumstances, the antitumour effect of radiotherapy has been observed outside of the radiation field, known as the abscopal effect. This phenomenon is proposed to have an immune origin and indicates that local radiotherapy elicits systemic effects. Herein, we highlight data that provide new mechanistic explanations for the success or failure of radiotherapy, and postulate how the combination of immune-modulation and radiation could tip the balance of the host immune response to promote cure. We use the concept of radiation- induced tumour equilibrium (RITE) as a starting point to discuss the mechanistic influence of immune-checkpoint therapies on radiotherapy efficacy.

Entities:  

Mesh:

Year:  2017        PMID: 28094262     DOI: 10.1038/nrclinonc.2016.211

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  242 in total

1.  Subversion of anticancer immunosurveillance by radiotherapy.

Authors:  Laurence Zitvogel; Guido Kroemer
Journal:  Nat Immunol       Date:  2015-10       Impact factor: 25.606

2.  Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome.

Authors:  Shruti Sharma; Rosane B DeOliveira; Parisa Kalantari; Peggy Parroche; Nadege Goutagny; Zhaozhao Jiang; Jennie Chan; Daniella C Bartholomeu; Fanny Lauw; J Perry Hall; Glen N Barber; Ricardo T Gazzinelli; Katherine A Fitzgerald; Douglas T Golenbock
Journal:  Immunity       Date:  2011-08-04       Impact factor: 31.745

3.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors:  Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal:  Lancet Oncol       Date:  2009-12-08       Impact factor: 41.316

5.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

6.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

7.  Phase I/II study of ipilimumab for patients with metastatic melanoma.

Authors:  Jeffrey S Weber; Steven O'Day; Walter Urba; John Powderly; Geoff Nichol; Michael Yellin; Jolie Snively; Evan Hersh
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

Authors:  Inge Verbrugge; Jim Hagekyriakou; Leslie L Sharp; Mara Galli; Alison West; Nicole M McLaughlin; Hélène Duret; Hideo Yagita; Ricky W Johnstone; Mark J Smyth; Nicole M Haynes
Journal:  Cancer Res       Date:  2012-05-08       Impact factor: 12.701

10.  STAT1 pathway mediates amplification of metastatic potential and resistance to therapy.

Authors:  Nikolai N Khodarev; Paul Roach; Sean P Pitroda; Daniel W Golden; Mihir Bhayani; Michael Y Shao; Thomas E Darga; Mara G Beveridge; Ravi F Sood; Harold G Sutton; Michael A Beckett; Helena J Mauceri; Mitchell C Posner; Ralph R Weichselbaum
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

View more
  270 in total

1.  Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery.

Authors:  Juan Carlos López Alfonso; Jan Poleszczuk; Rachel Walker; Sungjune Kim; Shari Pilon-Thomas; Jose J Conejo-Garcia; Hatem Soliman; Brian Czerniecki; Louis B Harrison; Heiko Enderling
Journal:  JCO Clin Cancer Inform       Date:  2019-04

2.  Intratumoral Immune Response to Gastric Cancer Varies by Molecular and Histologic Subtype.

Authors:  Teresa S Kim; Edaise da Silva; Daniel G Coit; Laura H Tang
Journal:  Am J Surg Pathol       Date:  2019-06       Impact factor: 6.394

3.  Impact of curative radiotherapy on the immune status of patients with localized prostate cancer.

Authors:  Franziska Eckert; Philipp Schaedle; Daniel Zips; Barbara Schmid-Horch; Hans-Georg Rammensee; Cihan Gani; Cécile Gouttefangeas
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

4.  Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy.

Authors:  Jelena Levi; Tina Lam; Samuel R Goth; Shahriar Yaghoubi; Jennifer Bates; Gang Ren; Salma Jivan; Tony L Huynh; Joseph E Blecha; Roli Khattri; Karl F Schmidt; Dominique Jennings; Henry VanBrocklin
Journal:  Cancer Res       Date:  2019-05-07       Impact factor: 12.701

Review 5.  Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.

Authors:  Meng Qiao; Tao Jiang; Caicun Zhou
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 6.  Ultrasound Hyperthermia Technology for Radiosensitization.

Authors:  Lifei Zhu; Michael B Altman; Andrei Laszlo; William Straube; Imran Zoberi; Dennis E Hallahan; Hong Chen
Journal:  Ultrasound Med Biol       Date:  2019-02-14       Impact factor: 2.998

7.  Harnessing radiation to improve immunotherapy: better with particles?

Authors:  Marco Durante; Silvia Formenti
Journal:  Br J Radiol       Date:  2019-07-22       Impact factor: 3.039

8.  The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.

Authors:  Daniel J Olson; Jason J Luke
Journal:  Immunotherapy       Date:  2019-02       Impact factor: 4.196

Review 9.  Clinical Development of Novel Drug-Radiotherapy Combinations.

Authors:  Saif S Ahmad; Marka R Crittenden; Phuoc T Tran; Paul G Kluetz; Gideon M Blumenthal; Helen Bulbeck; Richard D Baird; Kaye J Williams; Tim Illidge; Stephen M Hahn; Theodore S Lawrence; Patricia A Spears; Amanda J Walker; Ricky A Sharma
Journal:  Clin Cancer Res       Date:  2018-11-29       Impact factor: 12.531

Review 10.  Metastatic Complications of Cancer Involving the Central and Peripheral Nervous Systems.

Authors:  Joe S Mendez; Lisa M DeAngelis
Journal:  Neurol Clin       Date:  2018-06-15       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.